Logo image of PPBT

PURPLE BIOTECH LTD-ADR (PPBT) Stock Fundamental Analysis

NASDAQ:PPBT - Nasdaq - US74638P1093 - ADR - Currency: USD

2.68  -0.02 (-0.74%)

Fundamental Rating

2

Taking everything into account, PPBT scores 2 out of 10 in our fundamental rating. PPBT was compared to 195 industry peers in the Pharmaceuticals industry. While PPBT seems to be doing ok healthwise, there are quite some concerns on its profitability. PPBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PPBT has reported negative net income.
PPBT had a negative operating cash flow in the past year.
PPBT had negative earnings in each of the past 5 years.
PPBT had a negative operating cash flow in each of the past 5 years.
PPBT Yearly Net Income VS EBIT VS OCF VS FCFPPBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.55%, PPBT is in the better half of the industry, outperforming 61.03% of the companies in the same industry.
Looking at the Return On Equity, with a value of -22.03%, PPBT is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
Industry RankSector Rank
ROA -19.55%
ROE -22.03%
ROIC N/A
ROA(3y)-34.7%
ROA(5y)-32.74%
ROE(3y)-42.11%
ROE(5y)-37.99%
ROIC(3y)N/A
ROIC(5y)N/A
PPBT Yearly ROA, ROE, ROICPPBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PPBT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PPBT Yearly Profit, Operating, Gross MarginsPPBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, PPBT has more shares outstanding
Compared to 5 years ago, PPBT has more shares outstanding
Compared to 1 year ago, PPBT has an improved debt to assets ratio.
PPBT Yearly Shares OutstandingPPBT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
PPBT Yearly Total Debt VS Total AssetsPPBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -4.12, we must say that PPBT is in the distress zone and has some risk of bankruptcy.
PPBT has a Altman-Z score of -4.12. This is in the lower half of the industry: PPBT underperforms 60.00% of its industry peers.
There is no outstanding debt for PPBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.12
ROIC/WACCN/A
WACCN/A
PPBT Yearly LT Debt VS Equity VS FCFPPBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.23 indicates that PPBT has no problem at all paying its short term obligations.
The Current ratio of PPBT (2.23) is comparable to the rest of the industry.
PPBT has a Quick Ratio of 2.23. This indicates that PPBT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.23, PPBT is in line with its industry, outperforming 47.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 2.23
PPBT Yearly Current Assets VS Current LiabilitesPPBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

PPBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.43%, which is quite impressive.
EPS 1Y (TTM)71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PPBT Yearly Revenue VS EstimatesPPBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 200K 400K 600K 800K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PPBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PPBT Price Earnings VS Forward Price EarningsPPBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PPBT Per share dataPPBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PPBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PURPLE BIOTECH LTD-ADR

NASDAQ:PPBT (6/5/2025, 12:08:22 PM)

2.68

-0.02 (-0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-21 2025-05-21/bmo
Earnings (Next)08-14 2025-08-14
Inst OwnersN/A
Inst Owner Change-36.8%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.10M
Analysts0
Price TargetN/A
Short Float %6.94%
Short Ratio1.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-3.67
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.43
FCFYN/A
OCF(TTM)-5.43
OCFYN/A
SpS0
BVpS12.41
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.55%
ROE -22.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.7%
ROA(5y)-32.74%
ROE(3y)-42.11%
ROE(5y)-37.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 2.23
Altman-Z -4.12
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.32%
Cap/Depr(5y)46.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.89%
OCF growth 3YN/A
OCF growth 5YN/A